These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 25223350)

  • 1. Late effects of oxaliplatin-induced peripheral neuropathy (LEON)--cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years.
    Padman S; Lee J; Kumar R; Slee M; Hakendorf P; Richards A; Koczwara B; Kichenadasse G; Sukumaran S; Roy A; Vatandoust S; Karapetis CS
    Support Care Cancer; 2015 Mar; 23(3):861-9. PubMed ID: 25223350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors.
    Tofthagen C; Donovan KA; Morgan MA; Shibata D; Yeh Y
    Support Care Cancer; 2013 Dec; 21(12):3307-13. PubMed ID: 23903798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of oxaliplatin-induced neuropathy: a patient perspective.
    Bennett BK; Park SB; Lin CS; Friedlander ML; Kiernan MC; Goldstein D
    Support Care Cancer; 2012 Nov; 20(11):2959-67. PubMed ID: 22426503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study.
    Kokotis P; Schmelz M; Kostouros E; Karandreas N; Dimopoulos MA
    Clin Colorectal Cancer; 2016 Sep; 15(3):e133-40. PubMed ID: 27038553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxaliplatin treatment and peripheral nerve damage in cancer patients: A Polish cohort study.
    Banach M; Zygulska AL; Krzemieniecki K
    J Cancer Res Ther; 2018; 14(5):1010-1013. PubMed ID: 30197340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
    Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
    Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer.
    Vatandoust S; Joshi R; Pittman KB; Esterman A; Broadbridge V; Adams J; Singhal N; Yeend S; Price TJ
    Support Care Cancer; 2014 Feb; 22(2):513-8. PubMed ID: 24122404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies.
    Reddy SM; Vergo MT; Paice JA; Kwon N; Helenowski IB; Benson AB; Mulcahy MF; Nimeiri HS; Harden RN
    Clin Colorectal Cancer; 2016 Mar; 15(1):37-46. PubMed ID: 26337211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration.
    Beijers AJ; Mols F; Vreugdenhil G
    Support Care Cancer; 2014 Jul; 22(7):1999-2007. PubMed ID: 24728618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electroclinical biomarkers of early peripheral neurotoxicity from oxaliplatin.
    McHugh JC; Tryfonopoulos D; Fennelly D; Crown J; Connolly S
    Eur J Cancer Care (Engl); 2012 Nov; 21(6):782-9. PubMed ID: 22594346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Oncologist; 2011; 16(5):708-16. PubMed ID: 21478275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurotoxicity Outcomes in a Population-based Cohort of Elderly Patients Treated With Adjuvant Oxaliplatin for Colorectal Cancer.
    Raphael MJ; Fischer HD; Fung K; Austin PC; Anderson GM; Booth CM; Singh S
    Clin Colorectal Cancer; 2017 Dec; 16(4):397-404.e1. PubMed ID: 28434884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life.
    Stefansson M; Nygren P
    Acta Oncol; 2016; 55(9-10):1227-1235. PubMed ID: 27550718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.
    Briani C; Argyriou AA; Izquierdo C; Velasco R; Campagnolo M; Alberti P; Frigeni B; Cacciavillani M; Bergamo F; Cortinovis D; Cazzaniga M; Bruna J; Cavaletti G; Kalofonos HP
    J Peripher Nerv Syst; 2014 Dec; 19(4):299-306. PubMed ID: 25582667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.
    Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG
    J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer.
    Argyriou AA; Cavaletti G; Briani C; Velasco R; Bruna J; Campagnolo M; Alberti P; Bergamo F; Cortinovis D; Cazzaniga M; Santos C; Papadimitriou K; Kalofonos HP
    Cancer; 2013 Jan; 119(2):438-44. PubMed ID: 22786764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting acute and persistent neuropathy associated with oxaliplatin.
    Alejandro LM; Behrendt CE; Chen K; Openshaw H; Shibata S
    Am J Clin Oncol; 2013 Aug; 36(4):331-7. PubMed ID: 22547012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
    Leonard GD; Wright MA; Quinn MG; Fioravanti S; Harold N; Schuler B; Thomas RR; Grem JL
    BMC Cancer; 2005 Sep; 5():116. PubMed ID: 16168057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.